Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Elise D. Pieterman"'
Autor:
Casper Rokx, Jaime F Borjas Howard, Colette Smit, Ferdinand W Wit, Elise D Pieterman, Peter Reiss, Suzanne C Cannegieter, Willem M Lijfering, Karina Meijer, Wouter Bierman, Vladimir Tichelaar, Bart J A Rijnders, ATHENA observational HIV cohort
Publikováno v:
PLoS Medicine, Vol 17, Iss 5, p e1003101 (2020)
BACKGROUND:Multiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on the risk of recurrent VTE in this population are lacking, although this question is more impo
Externí odkaz:
https://doaj.org/article/c580179a2a4c4be0a209bd0ec7874d21
Autor:
Matthew D. Zimmerman, Elise D Pieterman, Han Wang, Lina Keutzer, Ulrika S. H. Simonsson, Aart van der Meijden, Hannelore I. Bax, Jurriaan E. M. de Steenwinkel, Sanne van den Berg
Publikováno v:
J Infect Dis
Journal of Infectious Diseases, 224(6), 1039-1047. Oxford University Press
Journal of Infectious Diseases, 224(6), 1039-1047. Oxford University Press
Background The treatment success rate of drug-resistant (DR) tuberculosis is alarmingly low. Therefore, more effective and less complex regimens are urgently required. Methods We compared the efficacy of an all oral DR tuberculosis drug regimen consi
Autor:
M. van der Valk, M.E.E. van Kasteren, Frank P. Kroon, Casper Rokx, M. Hillebregt, M.E. van der Ende, Selwyn H. Lowe, Emile F. Schippers, Jaime F Borjas Howard, S. Zaheri, J. W. Mulder, J. G. Den Hollander, Peter Reiss, Elise D. Pieterman, E. H. Gisolf, Bart J. A. Rijnders, Eliane M. S. Leyten, Colette Smit, Karina Meijer, Ferdinand W. N. M. Wit, Wouter F W Bierman, Kees Brinkman, Y. I. G. Vladimir Tichelaar
Publikováno v:
The Lancet HIV, 6(3), e173-e181. Elsevier Limited
The Lancet, 6(3), e173-e181. ELSEVIER SCIENCE INC
LANCET HIV, 6(3), e173-e181. Elsevier Ltd.
The Lancet, 6(3), e173-e181. ELSEVIER SCIENCE INC
LANCET HIV, 6(3), e173-e181. Elsevier Ltd.
BACKGROUND: The risk of venous thrombotic events is elevated in people with HIV, but overall risk estimates and estimates specific to immune status and antiretroviral medication remain i mprecise. In this study, we aimed to estimate these parameters
Autor:
S A A van den Berg, Hannelore I. Bax, J. E. M. de Steenwinkel, Elise D. Pieterman, Elin M. Svensson, A. van der Meijden
Publikováno v:
Antimicrobial Agents & Chemotherapy, 65(4):e02255-20. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 65, 4
Antimicrobial Agents and Chemotherapy, 65
Antimicrob Agents Chemother
Antimicrobial Agents and Chemotherapy, 65, 4
Antimicrobial Agents and Chemotherapy, 65
Antimicrob Agents Chemother
Improvements in the translational value of preclinical models can allow more-successful and more-focused research on shortening the duration of tuberculosis treatment. Although the hollow-fiber infection model (HFIM) is considered a valuable addition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb67f44c0548fb59e6943ffa52bd2170
https://pure.eur.nl/en/publications/a5380eb6-7a42-419e-ae2a-6cc35a2c3209
https://pure.eur.nl/en/publications/a5380eb6-7a42-419e-ae2a-6cc35a2c3209
Autor:
J. E. M. de Steenwinkel, Stewart T. Cole, Maarten J. Sarink, Claudia Sala, Elise D. Pieterman, Hannelore I. Bax
Publikováno v:
Antimicrobial Agents & Chemotherapy, 64(7):e00280-20. American Society for Microbiology
Antimicrob Agents Chemother
Antimicrob Agents Chemother
One of the reasons for the lengthy tuberculosis (TB) treatment is the difficulty to treat the nonmultiplying mycobacterial subpopulation. In order to assess the ability of (new) TB drugs to target this subpopulation, we need to incorporate dormancy m
Autor:
E. van Lochem, M. Scholing, P. Rombouts, A. Claessen, G. Blaauw, J. E. M. de Steenwinkel, Hannelore I. Bax, K.R.A. van Dijk, A. Reuwer, O. Pontesilli, Annelies Verbon, R. Leussenkamp-Hummelink, N. D. Van Burgel, M. Heron, I.H.M. van Loo, F.G. Liqui Lung, M. Hooghiemstra, Alewijn Ott, J. Berkhout, B. Mulder, V. Saegeman, C. W. Ang, Seppo Vainio, Elise D. Pieterman, A.H. Brandenburg
Publikováno v:
Tuberculosis, 108, 136-142. Churchill Livingstone
Tuberculosis (Edinburgh, Scotland), 108, 136-142. Churchill Livingstone
Pieterman, E D, Liqui Lung, F G, Verbon, A, Bax, H I, Ang, C W, Berkhout, J, Blaauw, G, Brandenburg, A, van Burgel, N D, Claessen, A, van Dijk, K, Heron, M, Hooghiemstra, M, Leussenkamp-Hummelink, R, van Lochem, E, van Loo, I H M, Mulder, B, Ott, A, Pontesilli, O, Reuwer, A, Rombouts, P, Saegeman, V, Scholing, M, Vainio, S & de Steenwinkel, J E M 2018, ' A multicentre verification study of the QuantiFERON ®-TB Gold Plus assay ', Tuberculosis, vol. 108, pp. 136-142 . https://doi.org/10.1016/j.tube.2017.11.014
Tuberculosis (Edinburgh, Scotland), 108, 136-142. Churchill Livingstone
Pieterman, E D, Liqui Lung, F G, Verbon, A, Bax, H I, Ang, C W, Berkhout, J, Blaauw, G, Brandenburg, A, van Burgel, N D, Claessen, A, van Dijk, K, Heron, M, Hooghiemstra, M, Leussenkamp-Hummelink, R, van Lochem, E, van Loo, I H M, Mulder, B, Ott, A, Pontesilli, O, Reuwer, A, Rombouts, P, Saegeman, V, Scholing, M, Vainio, S & de Steenwinkel, J E M 2018, ' A multicentre verification study of the QuantiFERON ®-TB Gold Plus assay ', Tuberculosis, vol. 108, pp. 136-142 . https://doi.org/10.1016/j.tube.2017.11.014
Objectives The aim of this verification study was to compare the QuantiFERON®-TB Gold Plus (QFT-Plus) to the QuantiFERON®-TB Gold In Tube (QFT-GIT). The new QFT-Plus test contains an extra antigen tube which, according to the manufacturer additiona
Autor:
Jurriaan E. M. de Steenwinkel, Hannelore I. Bax, Gerjo J. de Knegt, Jan-Willem C. Alffenaar, Lindsey H.M. te Brake, Rob E. Aarnoutse, Aart van der Meijden, Elise D. Pieterman
Publikováno v:
Antimicrobial Agents and Chemotherapy, 62,
Antimicrobial Agents and Chemotherapy, 62, 9, pp.
Antimicrobial Agents & Chemotherapy, 62(9):e01354-18. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 62(9):ARTN e01354-18. AMER SOC MICROBIOLOGY
Antimicrobial Agents and Chemotherapy, 62, 9, pp.
Antimicrobial Agents & Chemotherapy, 62(9):e01354-18. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 62(9):ARTN e01354-18. AMER SOC MICROBIOLOGY
The favorable treatment outcome rate for multidrug-resistant tuberculosis (MDR-TB) is only 54%, and therefore new drug regimens are urgently needed. In this study, we evaluated the activity of the combination of moxifloxacin and linezolid as a possib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d01c4c8c74f248e984803954fbe1dda8
https://europepmc.org/articles/PMC6125510/
https://europepmc.org/articles/PMC6125510/
Autor:
Vladimir Tichelaar, Bart J. A. Rijnders, Casper Rokx, James Francis Borjas-Howard, Wouter F W Bierman, Colette Smit, Elise D. Pieterman, Karina Meijer, Ferdinand W. N. M. Wit
Publikováno v:
Blood. 128:271-271
Introduction HIV-infected patients have an increased risk of venous thrombosis (VT), but the most recently published data are from before 2007 (Rasmussen et al. HIV Med2011). However, since 2008, recommended CD4+ T-cell thresholds for starting combin